Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.61 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1550206 | 0.87 | FFAR1 (0.77) | FFAR1ALOX15PTPN7ALDH1A1MEN1 | |
| SCHEMBL1551412 | 0.85 | FFAR1 (1.00) | FFAR1ALOX15PTPN7ALDH1A1MEN1 | |
| SCHEMBL1550667 | 0.85 | FFAR1 (0.74) | FFAR1ALOX15ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1778144 | 0.84 | FFAR1 (0.71) | FFAR1ALOX15PTPN7ALDH1A1MEN1 | |
| SCHEMBL1551462 | 0.84 | FFAR1 (1.00) | FFAR1ALOX15PTPN7ALDH1A1MEN1 | |
| SCHEMBL1550243 | 0.84 | FFAR1 (1.00) | FFAR1ALOX15PTGDR2SMN1; SMN2FFAR4 | |
| SCHEMBL1551092 | 0.84 | FFAR1 (0.72) | FFAR1ALOX15PTPN7ALDH1A1MEN1 | |
| SCHEMBL8127 | 0.83 | ALOX15 (1.00) | FFAR1ALOX15PTPN7ALDH1A1MEN1 | |
| SCHEMBL1318870 | 0.83 | ALOX15 (1.00) | FFAR1ALOX15PTPN7ALDH1A1MEN1 | |
| SCHEMBL339492 | 0.83 | ALOX15 (0.81) | FFAR1ALOX15PTPN7ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586607-B2 | Compounds for the treatment of metabolic diseases | SYDDANSK UNIVERSITET (DK) | 2013-11-19 | — | — | US | claimed |
| EP-2313360-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | UNIV SYDDANSK (DK) | 2012-09-05 | — | — | EP | claimed |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | claimed |
| EP-2313360-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | Syddansk Universitet (DK) | 2011-04-27 | — | — | EP | claimed |
| WO-2010012650-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET (DK) | 2010-02-04 | — | — | WO | claimed |
| WO-1999029640-A2 | COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF FIBROBLAST GROWTH FACTOR | EISAI CO., LTD. (JP) | 1999-06-17 | — | — | WO | claimed |
| US-8586607-B2 | Compounds for the treatment of metabolic diseases | SYDDANSK UNIVERSITET (DK) | 2013-11-19 | — | — | US | disclosed |
| US-8586607-B2 | Compounds for the treatment of metabolic diseases | SYDDANSK UNIVERSITET (DK) | 2013-11-19 | — | — | US | disclosed |
| EP-2313360-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | UNIV SYDDANSK (DK) | 2012-09-05 | — | — | EP | disclosed |
| EP-2313360-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | UNIV SYDDANSK (DK) | 2012-09-05 | — | — | EP | disclosed |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | disclosed |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | disclosed |
| EP-2313360-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | Syddansk Universitet (DK) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010012650-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET (DK) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010012650-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET (DK) | 2010-02-04 | — | — | WO | disclosed |
| WO-1999029640-A2 | COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF FIBROBLAST GROWTH FACTOR | EISAI CO., LTD. (JP) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | GPR119, INSR, GPR65 | FFAR1 6/4885ALOX15 763/4885PTPN7 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.